Ben-Gurion University Signs R&D Agreement with German Company curasan AG
Ben-Gurion University of the Negev’s technology transfer company BGN Technologies has signed a collaboration agreement with the German company curasan AG, to jointly develop special matrixes for bone regeneration. Curasan will invest 900,000 Euro in research to be performed by Dr. Hanna Rapaport and her team at Ben-Gurion University of the Negev, Israel (BGU).
The BGU research team led by Dr. Hanna Rapaport from the Avram and Stella Goldstein-Goren Department of Biotechnology Engineering has developed and patented a novel peptide matrix that can be used to significantly improve the process of bone regeneration. Within the research collaboration, curasan and Dr. Rapaport will combine curasan's existing inorganic products with the BGU bone regenerating peptide matrixes in order to develop and produce a variety of bone regeneration materials for orthopedic and dental uses.
“The funding that has been allocated will help us to develop a new generation of products which will significantly enhance bone regeneration while still retaining the characteristics provided by our existing purely inorganic absorbable materials,” explains Dr. Fabian Peters, Head of Research and Development of Biomaterials at curasan AG.
Dr. Rapaport noted that, "The aim of the research partnership is to create a variety of regenerative products which will combine the BGU peptides and the curasan products which will support the body’s own healing processes and encourage optimal bone regeneration".
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
